Lamivudine

also known as 3TC · Epivir · LAM · lamivudine (zeffix) · GR109714X · 3-thiacytidine · 3TC: lamivudine: Epivir · BCH 189, (-)- · +23 more

Other / unclassified

Developed for: HIV infectious disease · chronic hepatitis B virus infection · AIDS · tuberculosis · hepatitis B virus infection · lipodystrophy · hepatocellular carcinoma · amyotrophic lateral sclerosis
+20 more
· cirrhosis of liver · lymphoma · non-Hodgkin lymphoma · acute hepatitis B virus infection · Aicardi-Goutieres syndrome · cognitive impairment with or without cerebellar ataxia · colorectal cancer · disease related to solid organ transplantation · early-onset autosomal dominant Alzheimer disease · hepatitis D virus infection · HIV wasting syndrome · HIV-associated cancer · HIV-associated nephropathy · Kaposi's sarcoma · primary biliary cholangitis · refractory malignant neoplasm · Rett syndrome · small cell lung carcinoma · systemic lupus erythematosus · tropical spastic paraparesis
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · ViiV Healthcare · GlaxoSmithKline · Merck Sharp & Dohme LLC · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Glaxo Wellcome
+275 more
· Bristol-Myers Squibb · Gilead Sciences · ANRS, Emerging Infectious Diseases · Abbott · French National Agency for Research on AIDS and Viral Hepatitis · Hoffmann-La Roche · Boehringer Ingelheim · Fundacion Clinic per a la Recerca Biomédica · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Kirby Institute · Shanghai Public Health Clinical Center · Sun Yat-sen University · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Fight AIDS and Infectious Diseases Foundation · French National Institute of Health and Medical Research · Fundacion SEIMC-GESIDA · Fundación Huésped · Harvard School of Public Health (HSPH) · Novartis · Novartis Pharmaceuticals · PPD Development, LP · UNITAID · Beijing YouAn Hospital · Catholic University of the Sacred Heart · Germans Trias i Pujol Hospital · Janssen Pharmaceutica · Judit Pich · Macquarie University, Australia · Makerere University · Mexican Social Security Institute · National Center for AIDS/STD Control and Prevention, China CDC · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · PENTA Foundation · Peking Union Medical College · Pfizer · Pharmacia and Upjohn · Professor Francois Venter · University of California, San Diego · AIDS Care Research in Africa · AIDS Malignancy Consortium · Bill and Melinda Gates Foundation · CIHR Canadian HIV Trials Network · Centre Muraz · Chinese University of Hong Kong · Chulalongkorn University · Drugs for Neglected Diseases · Dupont Merck · Fudan University · Fundacion IDEAA · Hospital Authority, Hong Kong · Hospitales Universitarios Virgen del Rocío · Icahn School of Medicine at Mount Sinai · José Antonio Mata Marín · Juan A. Arnaiz · Korea University · Ministry of Science and Technology of the People´s Republic of China · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Mental Health (NIMH) · Radboud University Medical Center · St Vincent's Hospital, Sydney · Thai Red Cross AIDS Research Centre · The Second Hospital of Nanjing Medical University · University of British Columbia · University of Cape Town · University of Liege · University of North Carolina, Chapel Hill · University of Washington · Yunnan Provincial Infectious Disease Hospital · 407 Doctors · AIDS Project Los Angeles · AMS-CMU/IRD (PHPT) · AMS-PHPT Research Platform (Program for HIV Prevention and Treatment) · Achillion, a wholly owned subsidiary of Alexion · Advanced Pathogens Diagnostics Unit, University College London Hospitals · all 281 on the full record

Regulatory milestones approvals, filings & regulatory actions · 13 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed HIV infectious disease 3 milestones
Filed	US (FDA)	—	HIV infectious disease	2018-10-18	“submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC)” gsk.com ↗
Filed	EU (EMA)	—	HIV infectious disease	2018-09-14	“today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (DTG) and...” gsk.com ↗
Filed	US (FDA)	—	HIV infectious disease	2013-10-23	“ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine” gsk.com ↗
Approved Indication not stated 4 milestones
Label expansions (2)	US (FDA)	EPIVIR-HBV	—	2001-08-16 – 2018-11-15	fda.gov ↗
Label expansions (6)	US (FDA)	EPIVIR	—	1997-04-11 – 2016-07-20	fda.gov ↗
Approved	EU (EMA)	Epivir	—	1996-08-08	europa.eu ↗
Approved	US (FDA)	EPIVIR	—	1995-11-17	fda.gov ↗

Trials 332 · started per year

today

US approved 1995

EU approved 1996

1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT06056596	Jan → Sep 2024	rhegmatogenous retinal detachment	University of Wisconsin, Madison	Terminated	No outcome recorded
Phase 0	NCT05030025	Aug 2021	HIV infectious disease	Mylan Inc.	Completed	No outcome recorded
Phase 0	NCT04302896	Aug 2020 → Sep 2021	HIV infectious disease	Rhonda Brand	Completed	No outcome recorded
Phase 126 trials · 1 missed
Phase 1	NCT07058974	Aug 2025 → Jul 2026 overdue	—	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 1	NCT06811246	Feb → Jul 2024	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT04827134	May → Jul 2021	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT03441984	Feb → Apr 2018	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT02738931	May → Jun 2016	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT02591420	Apr 2016 → Mar 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 1	NCT02539576	Oct → Nov 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT01366547	Jun → Jul 2011	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT01220232	Nov 2010 → Jan 2011	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT00470041	Jun 2007 → Oct 2009	—	University Ghent	Completed	No outcome recorded
Phase 1	NCT02256774	Oct 2004 → May 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00336778	Jan 2004 → Apr 2008	HIV infectious disease	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 1	NCT01982396	Jan 2003 → Feb 2004	HIV infectious disease	PENTA Foundation	Completed	No outcome recorded
Phase 1	NCT00001968	Jan → Nov 2000	AIDS	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001644	Mar 1997 → Feb 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000902	? → Apr 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002183	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 1	NCT00000888	? → Apr 2001	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001091	? → Oct 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000865	? → Apr 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00014014	? → Aug 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000944	? → Mar 2003	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00004736	—	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000878	? → Oct 2001	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001108	? → Jun 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000920	? → Apr 2003	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT06494579	Sep 2024 → Jul 2026 overdue	refractory malignant neoplasm	Thomas Marron	Active not recruiting	No outcome recorded
Phase 1/2	NCT04552795	Feb 2021 → May 2023	early-onset autosomal dominant Alzheimer disease	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 1/2	NCT03760458	Sep 2020 → Dec 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT03836833	Jun → Nov 2019	HIV infectious disease	Drugs for Neglected Diseases	Unknown	No outcome recorded
Phase 1/2	NCT01528865	Dec 2015 → Aug 2017	lymphoma	University of Michigan Rogel Cancer Center	Withdrawn	No outcome recorded Stop: Business
Phase 1/2	NCT00672412	Oct 2008 → Jan 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT00312091	Dec 2006 → Sep 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 272 trials · 3 met primary · 2 missed
Phase 2	NCT07640503	Nov 2025 → Jun 2027 expected	Rett syndrome	Maria Denise Fernandes Carvalho de Andrade	Enrolling by invitation	No outcome recorded
Phase 2	NCT06640192	May 2025 → Dec 2026 expected	HIV infectious disease	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Recruiting	No outcome recorded
Phase 2	NCT06338826	Feb 2025 → Sep 2027 expected	HIV infectious disease	ANRS, Emerging Infectious Diseases	Not yet recruiting	No outcome recorded
Phase 2	NCT06519357	Oct 2024 → Sep 2025 overdue	cognitive impairment with or without cerebellar ataxia	Fight AIDS and Infectious Diseases Foundation	Active not recruiting	No outcome recorded
Phase 2	NCT06356740	Sep 2024 → Nov 2028 expected	systemic lupus erythematosus	Hospices Civils de Lyon	Not yet recruiting	No outcome recorded
Phase 2	NCT06034938	Feb 2024 → Apr 2026 overdue	HIV infectious disease	University Hospital, Caen	Recruiting	No outcome recorded
Phase 2	NCT04734652	Feb 2022 → Jan 2024	HIV infectious disease, pulmonary tuberculosis	Centre for the AIDS Programme of Research in South Africa	Completed	No outcome recorded
Phase 2	NCT04880785	Jul 2021 → Jun 2023	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 2	NCT04696575	Jul 2021 → Jul 2027 expected	small cell lung carcinoma	Roswell Park Cancer Institute	Recruiting	No outcome recorded
Phase 2	NCT03869944	Dec 2019 → Mar 2022	—	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
Phase 2	NCT03549689	Aug 2019 → Jul 2021	AIDS	Philip Grant	Withdrawn	No outcome recorded
Phase 2	NCT03539224	Nov 2017 → May 2021	HIV infectious disease	Instituto de Investigación Hospital Universitario La Paz	Unknown	No outcome recorded
Phase 2	NCT03144804	Oct 2017 → Mar 2020	colorectal cancer	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT04109183	Oct 2017 → Jan 2019	AIDS	Henan Genuine Biotech Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT02868580	Oct 2016 → Dec 2017	amyotrophic lateral sclerosis	Neuroscience Trials Australia	Completed	No outcome recorded
Phase 2	NCT02652260	Mar 2016 → Aug 2018	central nervous system disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT02629822	Jan 2016 → Nov 2018	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT02582684	Dec 2015 → Feb 2017	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 2	NCT02527096	Sep 2015 → Mar 2017	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT02363452	Sep 2015 → Jan 2018	Aicardi-Goutieres syndrome	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02566707	Aug 2015 → Dec 2016	HIV infectious disease	Radboud University Medical Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02116660	Sep 2014 → Jul 2017	HIV infectious disease	Merck Sharp & Dohme LLC	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01914744	Feb 2013 → Dec 2015	hepatitis B virus infection, non-Hodgkin lymphoma	Fudan University	Unknown	No outcome recorded
Phase 2	NCT01714414	Dec 2012 → Jun 2014	HIV infectious disease	Michael Hoelscher	Completed	No outcome recorded
Phase 2	NCT00949234	Mar → Jun 2010	HIV infectious disease	University of California, Los Angeles	Completed	No outcome recorded
Phase 2	NCT00958100	Aug 2009 → Nov 2010	AIDS	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 2	NCT00820118	May 2009 → May 2012	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT00270296	Jun 2006 → Mar 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00300573	Apr 2006	HIV infectious disease	Incyte Corporation	Terminated	No outcome recorded
Phase 2	NCT00099632	Mar 2006 → Apr 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00122538	Feb 2006 → Nov 2008	AIDS	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 2	NCT00307151	Dec 2005 → Dec 2010	HIV infectious disease	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	Met primary
Phase 2	NCT00167674	Nov 2003 → Mar 2005	HIV infectious disease	University of Washington	Completed	No outcome recorded
Phase 2	NCT00146380	Jul 2003 → Jan 2009	HIV infectious disease	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 2	NCT00226447	Dec 2002 → Jul 2006	chronic hepatitis B virus infection	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 2	NCT00041327	Oct 2002 → Dec 2006	lymphoma	AIDS Malignancy Consortium	Completed	No outcome recorded
Phase 2	NCT00043953	Aug 2002 → ?	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 2	NCT00120783	Feb 2002 → Aug 2003	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
Phase 2	NCT00034359	Feb 2002 → Jan 2003	chronic hepatitis B virus infection	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT00201318	Sep 2001 → Oct 2005	non-Hodgkin lymphoma	National Health Research Institutes, Taiwan	Completed	No outcome recorded
Phase 2	NCT00023309	Aug 2001 → Apr 2010	hepatitis B virus infection	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	Met primary
Phase 2	NCT00038220	Jul 2000 → ?	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 2	NCT00004852	Sep 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00002442	Jun 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00000940	May 1999 → Oct 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001457	Sep 1995 → Sep 2005	chronic hepatitis B virus infection, glomerulonephritis, hepatitis D virus infection, polyarteritis nodosa	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00000872	? → Jan 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000916	? → Aug 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002190	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT00001095	? → Oct 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002234	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00102206	? → May 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000831	? → May 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000838	? → Mar 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002379	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00124241	? → Feb 2003	chronic hepatitis B virus infection	Novartis	Completed	No outcome recorded
Phase 2	NCT00021463	? → Feb 2002	HIV infectious disease, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000885	? → Jun 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00001066	? → Jan 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002451	—	HIV infectious disease	Merck Sharp & Dohme LLC	Unknown	No outcome recorded
Phase 2	NCT00001067	? → Nov 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001068	? → Oct 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001083	? → Jun 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 2	NCT00002184	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00001085	? → Sep 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000882	? → May 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001084	? → Dec 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002241	—	HIV infectious disease	Merck Sharp & Dohme LLC	Unknown	No outcome recorded
Phase 2	NCT00002233	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00000918	? → Feb 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000891	? → May 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002227	—	HIV infectious disease	Dupont Merck	Completed	No outcome recorded

Phase 2/37 trials · 2 missed
Phase 2/3	NCT04337450	Apr 2022 → Sep 2025 overdue	HIV infectious disease	PENTA Foundation	Active not recruiting	No outcome recorded
Phase 2/3	NCT02150993	Jan 2016 → May 2019	—	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2/3	NCT02369406	May 2015 → Nov 2020 overdue	AIDS	Harvard School of Public Health (HSPH)	Active not recruiting	No outcome recorded
Phase 2/3	NCT01656122	Jul 2012 → Jul 2015	HIV infectious disease	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	Missed primary
Phase 2/3	NCT00490620	Jan 2004 → Apr 2007	primary biliary cholangitis	University of Alberta	Completed	No outcome recorded
Phase 2/3	NCT00039741	Aug 2002 → Aug 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 380 trials · 15 met primary · 5 missed
Phase 3	NCT07393659	May 2026 → Dec 2030 expected	HIV infectious disease	ViiV Healthcare	Not yet recruiting	No outcome recorded
Phase 3	NCT07075146	May 2025 → Jun 2026 overdue	HIV infectious disease, obesity disorder	José Antonio Mata Marín	Recruiting	No outcome recorded
Phase 3	NCT06658977	Nov 2024 → Jun 2025	amyotrophic lateral sclerosis	Macquarie University, Australia	Terminated	No outcome recorded
Phase 3	NCT06444620	Jul 2024 → Aug 2025 overdue	HIV infectious disease	University of Nairobi	Active not recruiting	No outcome recorded
Phase 3	NCT05979311	Feb 2024 → Apr 2026 overdue	HIV infectious disease	ViiV Healthcare	Active not recruiting	Met primary
Phase 3	NCT05735535	Oct 2023 → Sep 2025	HIV infectious disease	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Unknown	No outcome recorded
Phase 3	NCT05911360	Jul 2023 → Jan 2026	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT05917509	Jul 2023 → Sep 2025	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT05193994	Feb 2022 → Jun 2025	amyotrophic lateral sclerosis	Macquarie University, Australia	Terminated	No outcome recorded
Phase 3	NCT04808973	Jul 2021 → Aug 2023	HIV infectious disease, pregnancy disorder	Fundação Bahiana de Infectologia	Completed	No outcome recorded
Phase 3	NCT04867083	Jun 2021 → Jul 2023	HIV infectious disease	ANRS, Emerging Infectious Diseases	Unknown	Missed primary
Phase 3	NCT04979468	Mar 2021 → Apr 2023	HIV infectious disease	Societa' Italiana Di Malattie Infettive E Tropicali	Unknown	No outcome recorded
Phase 3	NCT04429152	Feb 2021 → Sep 2023	HIV infectious disease	Professor Francois Venter	Unknown	No outcome recorded
Phase 3	NCT04433780	Jan 2021 → Feb 2023	HIV infectious disease	Professor Francois Venter	Completed	No outcome recorded
Phase 3	NCT03870438	Dec 2019 → Sep 2022	HIV-associated cancer	ANRS, Emerging Infectious Diseases	Completed	Missed primary
Phase 3	NCT04051970	Nov 2019 → Jun 2022	HIV infectious disease	ANRS, Emerging Infectious Diseases	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT04021290	Nov 2019 → Apr 2021	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 3	NCT04034862	Oct 2019 → Mar 2023	HIV infectious disease	University of Liege	Completed	No outcome recorded
Phase 3	NCT03945981	Jul 2019 → Apr 2020	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT03682848	May 2019 → Dec 2021	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT03333083	May 2018 → Jun 2020	HIV infectious disease	Judit Pich	Terminated	No outcome recorded
Phase 3	NCT03311945	May 2018 → Mar 2021	HIV infectious disease	Judit Pich	Completed	No outcome recorded
Phase 3	NCT03446573	Jan 2018 → May 2019	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 3	NCT02831673	Jul 2016 → Mar 2018	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 3	NCT02831764	Jul 2016 → Apr 2018	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 3	NCT02588820	Apr 2016 → Nov 2018	HIV infectious disease	David Garcia Cinca	Unknown	No outcome recorded
Phase 3	NCT02284035	Sep 2015 → Feb 2017	AIDS	Juan A. Arnaiz	Completed	No outcome recorded
Phase 3	NCT02346487	Sep 2015 → May 2019	HIV infectious disease	Drugs for Neglected Diseases	Completed	No outcome recorded
Phase 3	NCT02397096	Jun 2015 → Feb 2018	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	Met primary
Phase 3	NCT02403674	Jun 2015 → Mar 2017	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	Met primary
Phase 3	NCT02075593	Dec 2014 → Oct 2018	HIV infectious disease, arthropathy	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT02263326	Dec 2014 → Jul 2017	HIV infectious disease	Babafemi Taiwo	Completed	No outcome recorded
Phase 3	NCT02231281	Aug 2014 → Aug 2018	—	Yongtao Sun, MD, PhD	Unknown	No outcome recorded
Phase 3	NCT02263079	Jun 2014 → Jan 2020	chronic hepatitis B virus infection	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT02105987	Apr 2014 → Apr 2015	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 3	NCT01910402	Aug 2013 → Sep 2015	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 3	NCT01936233	Aug 2013 → Dec 2021	hepatocellular carcinoma	Fudan University	Unknown	No outcome recorded
Phase 3	NCT01620944	Jul 2012 → Jan 2013	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded Stop: Business
Phase 3	NCT01352715	Mar 2012 → Oct 2014	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Met primary
Phase 3	NCT01511237	Dec 2011 → Jun 2015	HIV infectious disease	Research Institute for Development	Completed	No outcome recorded
Phase 3	NCT01440569	Sep 2011 → Aug 2012	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00796263	May 2009 → Jun 2033 expected	HIV infectious disease	SEARCH Research Foundation	Recruiting	No outcome recorded
Phase 3	NCT00605384	Aug 2008 → Feb 2009	chronic hepatitis B virus infection	Bristol-Myers Squibb	Terminated	No outcome recorded Stop: Business
Phase 3	NCT00332306	Jun 2006 → Jun 2009	HIV infectious disease, tuberculosis	Tuberculosis Research Centre, India	Unknown	No outcome recorded
Phase 3	NCT00118898	Sep 2005 → Nov 2009	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 3	NCT00120796	Aug 2005 → Jul 2008	chronic hepatitis B virus infection	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
Phase 3	NCT00102960	Jul 2005 → Sep 2012	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00338390	Apr 2005 → Feb 2007	HIV infectious disease	Hospital de Granollers	Completed	No outcome recorded
Phase 3	NCT00132652	Feb 2005 → Dec 2006	chronic hepatitis B virus infection	Novartis	Completed	No outcome recorded
Phase 3	NCT00074581	Feb 2005 → May 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT01095835	Feb 2005 → Jan 2010	chronic hepatitis B virus infection	Hoffmann-La Roche	Completed	Missed primary
Phase 3	NCT00314626	Nov 2004 → Feb 2007	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 3	NCT00078247	Oct 2004 → ?	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00323544	Oct 2004 → Jun 2007	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00131742	Jul 2004 → Jan 2007	chronic hepatitis B virus infection	Novartis	Completed	Met primary
Phase 3	NCT00094367	Jul 2004 → Oct 2005	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00275652	Jun 2004 → Aug 2007	cirrhosis of liver, hepatitis B virus infection	Mayo Clinic	Completed	No outcome recorded
Phase 3	NCT00099359	Feb 2004 → Feb 2011	HIV infectious disease	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT00158470	Sep 2003 → May 2007	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 3	NCT00053638	Feb 2003 → Oct 2004	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00057265	Feb 2003 → Apr 2006	chronic hepatitis B virus infection	Novartis	Completed	Met primary
Phase 3	NCT00144183	Jan 2003 → Jan 2007	AIDS	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00197613	Dec 2002 → Dec 2007	AIDS	Harvard School of Public Health (HSPH)	Completed	No outcome recorded
Phase 3	NCT00158405	Dec 2002 → Dec 2006	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	Mixed
Phase 3	NCT00135369	Sep 2002 → Jul 2005	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00046176	Aug 2002 → May 2004	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00044577	Jul 2002 → May 2004	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00140725	Apr 2000 → ?	chronic hepatitis B virus infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00002245	Apr 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00050895	? → Mar 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002436	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00002367	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00002208	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00002410	—	HIV infectious disease	Dupont Merck	Completed	No outcome recorded
Phase 3	NCT00002124	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded
Phase 3	NCT00002397	—	HIV infectious disease, HIV-associated nephropathy	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00002320	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00013520	? → Jun 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00028327	? → Jul 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002416	—	HIV infectious disease	Triangle Pharmaceuticals	Completed	No outcome recorded

Phase 498 trials · 14 met primary · 4 missed
Phase 4	NCT07357584	Sep 2026 → Apr 2028 expected	HIV infectious disease	Fundación Huésped	Recruiting	No outcome recorded
Phase 4	NCT06967753	Jul 2025 → Dec 2026 expected	HIV infectious disease	UBATEC	Recruiting	No outcome recorded
Phase 4	NCT07031063	Apr 2025 → Dec 2026 expected	HIV infectious disease, metabolic syndrome X	Mexican Social Security Institute	Recruiting	No outcome recorded
Phase 4	NCT06337032	Aug 2024 → Mar 2034 expected	HIV infectious disease	Gilead Sciences	Recruiting	No outcome recorded
Phase 4	NCT06602622	Aug 2024 → Nov 2025 overdue	HIV wasting syndrome	Mexican Social Security Institute	Recruiting	No outcome recorded
Phase 4	NCT06503796	Aug 2024 → Nov 2025 overdue	hepatitis B virus infection	Beijing 302 Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06485154	Jun 2024 → Jun 2026 overdue	—	University of Witwatersrand, South Africa	Recruiting	No outcome recorded
Phase 4	NCT05289986	Nov 2023 → Nov 2024	HIV infectious disease	Chelsea and Westminster NHS Foundation Trust	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT06037564	Nov 2023 → Oct 2026 expected	HIV infectious disease	Insel Gruppe AG, University Hospital Bern	Enrolling by invitation	No outcome recorded
Phase 4	NCT06907056	Nov 2023 → Feb 2026 overdue	HIV infectious disease	José Antonio Mata Marín	Recruiting	No outcome recorded
Phase 4	NCT07006246	May 2023 → Nov 2025 overdue	HIV infectious disease	Professor Francois Venter	Active not recruiting	No outcome recorded
Phase 4	NCT05493969	Aug 2022 → Aug 2025	AIDS	Shanghai Public Health Clinical Center	Unknown	No outcome recorded
Phase 4	NCT04884139	Jul 2021 → Feb 2024	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	Met primary
Phase 4	NCT04880395	May 2021 → May 2024	HIV infectious disease	Fundación Huésped	Completed	No outcome recorded
Phase 4	NCT04665375	Apr 2021 → Mar 2024	HIV infectious disease	University Health Network, Toronto	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04183738	Feb 2021 → Dec 2022	Epstein-Barr virus infection, HIV infectious disease, cytomegalovirus infection, human herpesvirus 8 infection +1	Kirby Institute	Withdrawn	No outcome recorded
Phase 4	NCT04549467	Nov 2020 → Sep 2023	HIV infectious disease	Fundacion IDEAA	Completed	Met primary
Phase 4	NCT04233372	Aug 2020 → Jul 2022	HIV infectious disease	Hospital Clinic of Barcelona	Completed	No outcome recorded
Phase 4	NCT04295460	Mar 2020 → Jan 2022	HIV infectious disease	Hospitales Universitarios Virgen del Rocío	Unknown	Missed primary
Phase 4	NCT03675815	Dec 2019 → Jan 2024	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT05295394	May 2019 → Aug 2022	HIV infectious disease	Pedro Cahn	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT03360682	Apr 2018 → May 2020	HIV infectious disease, disease related to solid organ transplantation	Fundacion Clinic per a la Recerca Biomédica	Completed	No outcome recorded
Phase 4	NCT02935075	Mar 2018 → Jun 2019	HIV infectious disease	Shanghai Public Health Clinical Center	Completed	No outcome recorded
Phase 4	NCT02945163	Mar 2018 → Jun 2019	HIV infectious disease	Shanghai Public Health Clinical Center	Completed	No outcome recorded
Phase 4	NCT03017872	Nov 2017 → Nov 2022	HIV infectious disease	Kirby Institute	Unknown	Met primary
Phase 4	NCT03447873	Jun 2017 → Sep 2020	HIV infectious disease	Hospitales Universitarios Virgen del Rocío	Completed	No outcome recorded
Phase 4	NCT03642704	Feb 2017 → Sep 2019	—	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 4	NCT02659761	Nov 2016 → Sep 2021	HIV infectious disease	University College Dublin	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02712801	Apr 2016 → Dec 2021	HIV infectious disease	National Center for Women and Children's Health, China CDC	Completed	No outcome recorded
Phase 4	NCT02634073	Jan → Mar 2016	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 4	NCT02770508	Nov 2015 → Jul 2017	HIV infectious disease	Fundación Huésped	Completed	Met primary
Phase 4	NCT02509195	Aug 2015 → Feb 2017	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 4	NCT02560649	May 2015 → Aug 2016	chronic hepatitis B virus infection	Ruijin Hospital	Unknown	No outcome recorded
Phase 4	NCT02632474	Apr 2015 → Dec 2016	HIV infectious disease	Shanghai Public Health Clinical Center	Completed	No outcome recorded
Phase 4	NCT02246998	Dec 2014 → Jan 2016	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT02211482	Oct 2014 → Mar 2016	HIV infectious disease	Fundación Huésped	Completed	Met primary
Phase 4	NCT01599364	Apr 2014 → Apr 2016	HIV infectious disease	Catholic University of the Sacred Heart	Completed	Met primary
Phase 4	NCT01928511	Jan 2014 → Dec 2018	chronic hepatitis B virus infection	Seng Gee Lim	Completed	Met primary
Phase 4	NCT01894269	Jul 2013 → Jul 2015	hepatocellular carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 4	NCT01367236	Jan 2013 → Oct 2015	HIV infectious disease, cognitive disorder	Imperial College London	Completed	Missed primary
Phase 4	NCT01693679	Sep 2012 → Apr 2014	cirrhosis of liver	Shao-quan Zhang	Unknown	No outcome recorded
Phase 4	NCT01627223	Jul 2012 → Apr 2016	chronic hepatitis B virus infection	Taichung Veterans General Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01471821	Oct 2011 → Apr 2014	HIV infectious disease	Juan A. Arnaiz	Completed	Met primary
Phase 4	NCT01307488	Sep 2011 → Apr 2014	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	Met primary
Phase 4	NCT01275625	Jun 2011 → Oct 2012	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT01354652	May 2011 → Sep 2013	lactic acidosis	Asan Medical Center	Terminated	No outcome recorded
Phase 4	NCT01751555	Feb 2011 → Jun 2013	HIV infectious disease	National Center for AIDS/STD Control and Prevention, China CDC	Completed	No outcome recorded
Phase 4	NCT01075152	Nov 2010 → Oct 2012	AIDS, Cryptococcal meningitis	University of Minnesota	Completed	Missed primary
Phase 4	NCT01059422	Oct 2010 → Mar 2013	HIV infectious disease, tuberculosis	Central Institute of Epidemiology, Moscow, Russia	Completed	No outcome recorded
Phase 4	NCT01102972	Apr 2010 → Jun 2012	HIV infectious disease	ViiV Healthcare	Completed	Met primary
Phase 4	NCT01546116	Feb 2010 → Feb 2012	chronic hepatitis B virus infection	Korea University	Completed	No outcome recorded
Phase 4	NCT00955968	Jan 2010 → Aug 2016	HIV infectious disease	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	No outcome recorded
Phase 4	NCT01014481	Oct 2009 → May 2011	HIV infectious disease, tuberculosis	Bamrasnaradura Infectious Diseases Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01005238	Sep 2009 → Dec 2014	chronic hepatitis B virus infection	University Hospital, Basel, Switzerland	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00885482	May 2009 → May 2010	HIV infectious disease	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 4	NCT00753324	May 2009 → Jan 2012	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	Met primary
Phase 4	NCT00872417	Mar → Dec 2009	AIDS	Peking Union Medical College	Unknown	No outcome recorded
Phase 4	NCT01788371	Mar 2009 → Jul 2012	chronic hepatitis B virus infection	Hua Zhang	Completed	No outcome recorded
Phase 4	NCT01743079	Jan 2009 → Jul 2013	chronic hepatitis B virus infection	Beijing YouAn Hospital	Completed	No outcome recorded
Phase 4	NCT01088516	Dec 2008 → Nov 2011	HIV infectious disease	University of Zambia	Completed	No outcome recorded
Phase 4	NCT00865475	Dec 2008 → Mar 2013	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT01772940	Dec 2008 → Oct 2011	HIV infectious disease	Centre Hospitalier Universitaire Saint Pierre	Completed	Missed primary
Phase 4	NCT00555334	Nov 2007 → Dec 2009	hepatocellular carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 4	NCT00768157	Apr 2007 → Aug 2009	hepatitis B virus infection, hepatocellular carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 4	NCT00531167	Apr 2007 → Apr 2011	chronic hepatitis B virus infection	Korea University	Completed	No outcome recorded
Phase 4	NCT00810524	Jan 2007 → Jan 2017	chronic hepatitis B virus infection	Sun Yat-sen University	Unknown	No outcome recorded
Phase 4	NCT00455585	Jan → May 2007	HIV infectious disease	Makerere University	Completed	No outcome recorded
Phase 4	NCT00337922	Jul 2006 → ?	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00389194	Apr 2006 → Oct 2008	HIV infectious disease	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00356616	Sep 2005 → Jun 2007	HIV infectious disease	Germans Trias i Pujol Hospital	Terminated	No outcome recorded
Phase 4	NCT00244712	Jul 2005 → Apr 2008	HIV infectious disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00084136	May 2005 → May 2010	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Mixed
Phase 4	NCT00335192	Jan → Sep 2005	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 4	NCT00618176	Jan 2005 → Sep 2006	HIV infectious disease	Peking Union Medical College	Completed	No outcome recorded
Phase 4	NCT00192621	Nov 2004 → Dec 2006	HIV infectious disease, cardiovascular disorder, glucose metabolism disease, hyperlipidemia +1	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00851630	Jun 2004 → Sep 2007	HIV infectious disease, tuberculosis	Duke University	Completed	No outcome recorded
Phase 4	NCT00214435	May 2004 → ?	AIDS	407 Doctors	Unknown	No outcome recorded
Phase 4	NCT00082394	Apr 2004 → Mar 2006	HIV infectious disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00143728	Jan 2004 → May 2010	HIV infectious disease	University of British Columbia	Suspended	No outcome recorded Stop: Enrollment
Phase 4	NCT00122668	Nov 2003 → Jul 2005	HIV infectious disease, lipodystrophy	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
Phase 4	NCT00144157	Jun 2003 → Jul 2006	AIDS	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00643968	Mar 2003 → Jun 2005	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00192660	Feb 2003 → Oct 2006	cardiovascular disorder, lipodystrophy	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00380770	Jan 2003 → Feb 2009	AIDS, Kaposi's sarcoma, human herpesvirus 8 infection	University of KwaZulu	Completed	No outcome recorded
Phase 4	NCT00122226	Jan 2003 → Jul 2008	HIV infectious disease, lipodystrophy	Amsterdam UMC, location VUmc	Unknown	No outcome recorded
Phase 4	NCT00143689	Apr 2002 → Feb 2008	HIV infectious disease	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT00116116	Mar 2002 → Jun 2005	AIDS	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT00038506	Mar 2002 → Aug 2004	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT00354653	Feb 2002 → Jan 2007	chronic hepatitis B virus infection	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT00380614	Jan 2002 → Mar 2005	acute hepatitis B virus infection	Maulana Azad Medical College	Completed	No outcome recorded
Phase 4	NCT00011895	Feb 2001 → ?	HIV infectious disease	GlaxoSmithKline	Unknown	No outcome recorded
Phase 4	NCT00338780	Nov 2000 → Jan 2005	chronic hepatitis B virus infection	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT00006190	Nov 2000 → Nov 2001	HIV infectious disease, lipodystrophy	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 4	NCT00005764	May 2000 → ?	HIV infectious disease, lipodystrophy	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00004585	Oct 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00002386	—	HIV infectious disease, hemophilia A	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00002179	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00002376	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase not applicable39 trials · 1 met primary · 3 missed
—	NCT05477407	Oct 2022 → Mar 2024	HIV infectious disease	Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida	Completed	No outcome recorded
—	NCT03394196	Jul 2018 → May 2020	—	University of Washington	Terminated	No outcome recorded Stop: Business
—	NCT03275701	Jul 2016 → Oct 2019	HIV infectious disease	Mills Clinical Research	Unknown	No outcome recorded
—	NCT02652793	Nov 2015 → Nov 2018	HIV infectious disease	Judit Pich	Completed	No outcome recorded
—	NCT02384395	Sep 2015 → Mar 2020	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT01844297	May 2013 → Oct 2015	AIDS	Peking Union Medical College	Unknown	No outcome recorded
—	NCT00091936	Aug 2009 → ?	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT01344148	Feb 2009 → Jun 2011	AIDS	Shanghai Public Health Clinical Center	Unknown	No outcome recorded
—	NCT00872872	May 2008 → Apr 2019	—	Thai Red Cross AIDS Research Centre	Completed	No outcome recorded
—	NCT00860626	Jan 2008 → Dec 2009	chronic hepatitis B virus infection	Sun Yat-sen University	Unknown	No outcome recorded
—	NCT00120510	Jul 2007 → Sep 2009	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
—	NCT00100646	Mar 2007 → Mar 2010	HIV infectious disease	The Wistar Institute	Completed	Missed primary
—	NCT00830856	Oct 2006 → Oct 2008	Cryptococcal meningitis, HIV infectious disease	University of Zimbabwe	Completed	Missed primary
—	NCT00100568	Jul 2006 → Jun 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00489151	Jun 2005 → Dec 2007	hepatitis B virus infection	Hospital Authority, Hong Kong	Unknown	No outcome recorded
—	NCT00100594	May 2005 → May 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00080522	Feb 2005 → Jan 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00152061	Jan → Aug 2005	HIV infectious disease	Stanford University	Completed	No outcome recorded
—	NCT00516945	Sep 2004 → Jun 2008	hepatitis B virus infection, neoplasm	Hospital Authority, Hong Kong	Completed	No outcome recorded
—	NCT00116415	Mar 2002 → Nov 2004	AIDS	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00001119	Oct 1999 → Jun 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002411	Mar 1998 → Sep 1999	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00006617	? → Jun 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002203	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00006443	? → Oct 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002401	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded
—	NCT00001075	? → Jul 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000922	? → Jan 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
—	NCT00002108	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002168	—	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00014937	? → Dec 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00100581	? → Jan 2007	HIV infectious disease, hepatitis C virus infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002407	—	HIV infectious disease	Weill Medical College of Cornell University	Completed	No outcome recorded
—	NCT00002155	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00004855	? → Apr 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00006578	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
—	NCT00000919	? → Nov 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00001080	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
—	NCT00002400	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded

Comparator or background therapy266 trials
Phase 0	NCT00719602 Comparator	Aug 2009 → Aug 2013	HIV infectious disease, malaria	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	No outcome recorded
Phase 1	NCT07115368 Background	Aug → Sep 2025	HIV infectious disease	Gilead Sciences	Terminated	No outcome recorded Stop: Business
Phase 1	NCT07001319 Background	May 2025 → Mar 2026	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 1	NCT06428045 Background	Apr 2025 → Apr 2029 expected	malignant glioma	University of Miami	Recruiting	No outcome recorded
Phase 1	NCT05585307 Background	Oct 2022 → Feb 2024	HIV infectious disease	Gilead Sciences	Completed	Met primary
Show all 266 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 75

Date	Issuer	Release
2026-07-29	GlaxoSmithKline	Results Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 gsk.com ↗ Confirmed viral rebound occurred in 0.9% (n=2/235) of adolescents receiving CAB+RPV LA versus 6.4% (n=15/241) receiving daily oral therapy.
2026-07-29	ViiV Healthcare	Results CABENUVA DEMONSTRATES SUPERIORITY TO DAILY ORAL THERAPY IN ADOLESCENTS LIVING WITH HIV, AS ViiV HEALTHCARE HIGHLIGHTS NEW LONG-ACTING INJECTABLE DATA AT AIDS 2026 viivhealthcare.com ↗ Week 96 results from the LATA trial, led by University College London, showed CAB+RPV LA dosed every two months was superior to daily oral dolutegravir/tenofovir disoproxil fumarate/lamivudine (DTG/TDF/3TC) in 476 virologically suppressed adolescents aged 12 to 19 years living with HIV in Kenya, South Africa, Uganda and Zimbabwe.
2026-07-27	GlaxoSmithKline	Results ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV gsk.com ↗ Data show that Dovato (dolutegravir/lamivudine (DTG/3TC)) demonstrated non-inferior efficacy to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in treatment-naïve adults living with HIV, including people with high viral loads or a low CD4+ cell count1.
2026-07-27	ViiV Healthcare	Results ViiV HEALTHCARE’S 2-DRUG REGIMEN DOVATO IS AS EFFECTIVE AS 3-DRUG REGIMEN BIKTARVY IN FIRST-OF-ITS-KIND HEAD-TO-HEAD STUDY IN TREATMENT-NAÏVE ADULTS LIVING WITH HIV viivhealthcare.com ↗ Data show that Dovato (dolutegravir/lamivudine (DTG/3TC)) demonstrated non-inferior efficacy to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in treatment-naïve adults living with HIV, including people with high viral loads or a low CD4+ cell count.
2026-02-23	ViiV Healthcare	Results ViiV HEALTHCARE ANNOUNCES DATA SHOWING SWITCHING TO DOVATO WAS ASSOCIATED WITH A LOWER PROPORTION OF STEATOTIC LIVER DISEASE VERSUS BIKTARVY FOR HIV-1 TREATMENT viivhealthcare.com ↗ Steatotic liver disease, an increasingly recognised comorbidity in people living with HIV, was reported in 49% (n=26/53) of participants switching to BIC/FTC/TAF versus 29% (n=17/58) switching to DTG/3TC
2025-07-14	GlaxoSmithKline	Results ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression gsk.com ↗ Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) across a broad range of populations
2025-07-14	ViiV Healthcare	Results ViiV HEALTHCARE DATA SHOW 89% OF TREATMENT-NAÏVE PEOPLE WITH HIV CHOOSE TO SWITCH TO LONG-ACTING INJECTABLE VOCABRIA + REKAMBYS FROM DAILY PILLS AFTER ACHIEVING RAPID VIRAL SUPPRESSION viivhealthcare.com ↗
2025-03-12	Merck Sharp & Dohme LLC	Results Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48 merck.com ↗ In the double-blind trial MK-8591A-052 (Abstract #204A), results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.5% of participants who switched to DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 0.6% on BIC/FTC/TAF (treatment difference 0.9%, 95% CI -1.9, 2.9).
2024-11-07	ViiV Healthcare	Results ViiV HEALTHCARE EXPANDS ON REAL-WORLD DATA SUPPORTING USE OF LONG-ACTING THERAPIES IN DIVERSE PATIENT POPULATIONS AT HIV GLASGOW viivhealthcare.com ↗ RUMBA’s week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF
2024-10-10	ViiV Healthcare	Results GSK AND ViiV HEALTHCARE TO SHOWCASE ADVANCES ACROSS INDUSTRY-LEADING INFECTIOUS DISEASE PORTFOLIO AT IDWEEK 2024 viivhealthcare.com ↗ People with HIV in the US switching to cabotegravir + rilpivirine long-acting (CAB+RPV LA) from oral antiretroviral therapy (ART) have numerous real-world benefits, including high adherence and treatment satisfaction
2024-07-23	GlaxoSmithKline	Results ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1 gsk.com ↗ Findings showed that switching to DTG/3TC in virologically suppressed adults living with HIV demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF.
2024-07-23	ViiV Healthcare	Results ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING 2-DRUG REGIMEN DOVATO IS AS EFFECTIVE AS 3-DRUG REGIMEN BIKTARVY FOR MAINTENANCE THERAPY OF HIV-1 viivhealthcare.com ↗ Findings showed that switching to DTG/3TC in virologically suppressed adults living with HIV demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF.
2024-02-28	GlaxoSmithKline	Results ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV gsk.com ↗ A single once-daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6kg
2023-10-10	GlaxoSmithKline	Results GSK and ViiV Healthcare to present scientific advancements in their industry-leading infectious diseases portfolio at IDWeek 2023 gsk.com ↗ Virological suppression in people with HIV-1 (PWH) receiving dolutegravir/lamivudine was high and similar across age groups despite older PWH having increased rates of comorbidities and polypharmacy (TANDEM subgroup analysis) (encore)
2023-09-05	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Regulatory Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV viatris.com ↗ The FDA's tentative approval through the President's Emergency Plan for AIDS Relief (PEPFAR) program means the formulation meets all the agency's quality, safety, and efficacy standards.
2022-06-14	Drugs for Neglected Diseases	Regulatory Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa dndi.org ↗ The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, ‘4-in-1’ fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV.
2022-03-30	GlaxoSmithKline	Regulatory ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV gsk.com ↗
2022-03-30	ViiV Healthcare	Regulatory ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF TRIUMEQ PD, THE FIRST DISPERSIBLE SINGLE TABLET REGIMEN CONTAINING DOLUTEGRAVIR, A ONCE-DAILY TREATMENT FOR CHILDREN LIVING WITH HIV viivhealthcare.com ↗
2021-10-27	Merck Sharp & Dohme LLC	Results Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021 merck.com ↗ Phase 2b data through 144 weeks demonstrated that islatravir combined with doravirine continued to maintain viral suppression, as measured by the number of study participants achieving HIV-1 RNA levels <50 copies/mL, similar to DOR/3TC/TDF.
2021-10-25	Merck Sharp & Dohme LLC	Results Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection merck.com ↗ At 48 weeks, both trials met their primary efficacy endpoint of percentage of participants with HIV-1 RNA levels ≥50 copies/mL, demonstrating that antiviral efficacy was comparable between DOR/ISL and ART (ILLUMINATE SWITCH A) and between DOR/ISL and BIC/FTC/TAF (ILLUMINATE SWITCH B).
2021-10-04	GlaxoSmithKline	Regulatory ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV gsk.com ↗
2021-10-04	ViiV Healthcare	Regulatory ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV viivhealthcare.com ↗
2021-07-17	GlaxoSmithKline	Results ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 gsk.com ↗ After three years of therapy, dolutegravir/lamivudine maintained non-inferior virologic efficacy compared with a TBR, with no confirmed virologic withdrawals or resistance development noted in the dolutegravir/lamivudine treatment arm.
2021-07-17	ViiV Healthcare	Results ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 viivhealthcare.com ↗ Injection site reactions were the most common drug-related adverse event; most were Grade 1 or 2 (99.5%).
2020-10-05	GlaxoSmithKline	Results ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1 gsk.com ↗ Dolutegravir plus lamivudine continues to demonstrate long-term non-inferior efficacy compared to dolutegravir plus TDF/FTC with benefits beyond viral suppression.
2020-10-05	ViiV Healthcare	Results ViiV HEALTHCARE ANNOUNCES DOLUTEGRAVIR PLUS LAMIVUDINE THREE-YEAR DATA CONFIRMING LONG-TERM VIRAL SUPPRESSION NON-INFERIOR TO A 3-DRUG REGIMEN FOR TREATMENT-NAÏVE ADULTS WITH HIV-1 viivhealthcare.com ↗ Dolutegravir plus lamivudine continues to demonstrate long-term non-inferior efficacy compared to dolutegravir plus TDF/FTC with benefits beyond viral suppression.
2020-07-02	GlaxoSmithKline	Results ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) gsk.com ↗ Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): the TANGO study
2020-03-11	Janssen Research & Development, LLC	Results Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 Weeks jnj.com ↗ The study – First Long-Acting Injectable Regimen (FLAIR) trial – demonstrated positive 96-week results in long-term safety and efficacy of rilpivirine and cabotegravir.
2020-03-09	ViiV Healthcare	Results ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting injectable treatment regimen in adults living with HIV-1 viivhealthcare.com ↗ The study demonstrated that the 2DR of once-monthly cabotegravir and rilpivirine continued to provide non-inferior efficacy and comparable safety to the daily, oral, three-drug regimen of Triumeq (abacavir/dolutegravir/lamivudine-ABC/DTG/3TC) at Week 96.
2019-11-06	GlaxoSmithKline	Results EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV gsk.com ↗ Week 48 data showing that switching to dolutegravir/lamivudine from a 3-drug TAF-based regimen was not associated with a higher frequency of intermittent viremia
2019-11-06	Gilead Sciences	Results Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials gilead.com ↗ Across all treatment groups no participants developed treatment failure with treatment-emergent resistance.
2019-11-06	ViiV Healthcare	Results EACS 2019: ViiV HEALTHCARE TO PRESENT 17 ABSTRACTS FROM ITS PORTFOLIO ADDRESSING THE DIVERSE NEEDS OF PEOPLE LIVING WITH HIV viivhealthcare.com ↗ Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study
2019-09-20	Merck Sharp & Dohme LLC	Regulatory Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed merck.com ↗
2019-07-24	GlaxoSmithKline	Results ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance gsk.com ↗ Both the GEMINI 1 & 2 studies showed that dolutegravir plus lamivudine continued to offer non-inferior efficacy to dolutegravir plus TDF/FTC at Week 96.
2019-07-24	ViiV Healthcare	Results ViiV HEALTHCARE PRESENTS GEMINI 1 & 2 STUDIES THROUGH WEEK 96 SHOWING 2-DRUG REGIMEN OF DOLUTEGRAVIR PLUS LAMIVUDINE CONTINUES TO DEMONSTRATE HIGH EFFICACY RATES AND NO CASES OF TREATMENT EMERGENT RESISTANCE viivhealthcare.com ↗ Both the GEMINI 1 & 2 studies showed that dolutegravir plus lamivudine continued to offer non-inferior efficacy to dolutegravir plus TDF/FTC at Week 96.
2019-07-24	ViiV Healthcare	Results ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection viivhealthcare.com ↗ Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that data from the phase III TANGO study showed that the 2-drug regimen (2DR) of Dovato▼ (dolutegravir/lamivudine) has similar efficacy to a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs in virally suppressed adults with HIV-1.
2019-03-07	GlaxoSmithKline	Results ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection gsk.com ↗ The study found virologic suppression rates (HIV-1 RNA <50 c/mL) at Week 48 were similar between treatment arms (cabotegravir + rilpivirine: 265/283 [93.6%], Triumeq: 264/283 [93.3%], adjusted difference: 0.4%. 95% CI: -3.7, 4.5).
2018-11-28	Merck Sharp & Dohme LLC	Regulatory European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in… merck.com ↗ Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO™ and PIFELTRO™ for the treatment of HIV-1 infection.
2018-10-30	GlaxoSmithKline	Results ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen gsk.com ↗ The study showed long-acting cabotegravir and rilpivirine, injected once a month, had similar efficacy to Triumeq at Week 48 based on the proportion of participants with plasma HIV-1 RNA ≥50 copies per millilitre [c/mL] using the FDA Snapshot algorithm.
2018-10-18	GlaxoSmithKline	Regulatory ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV gsk.com ↗ ViiV Healthcare today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
2018-10-04	Merck Sharp & Dohme LLC	Results Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens merck.com ↗
2018-10-04	Merck Sharp & Dohme LLC	Results Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients merck.com ↗ The efficacy findings at Week 96 in DRIVE-AHEAD were consistent with the findings at Week 48 in which DELSTRIGO demonstrated non-inferior efficacy in comparison to a fixed-dose combination of efavirenz (EFV, 600 mg), emtricitabine (FTC, 200 mg) and TDF (300 mg).
2018-10-03	Gilead Sciences	Results Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine (600/50/300mg, ABC /DTG/3TC) through 96 weeks of therapy.
2018-09-20	Merck Sharp & Dohme LLC	Regulatory Merck Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO™ (doravirine) in the European Union for the Treatment of HIV-1 Infection merck.com ↗
2018-09-14	GlaxoSmithKline	Regulatory ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV gsk.com ↗ London, UK ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
2018-08-30	Merck Sharp & Dohme LLC	Regulatory FDA Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients merck.com ↗ Today’s approvals of DELSTRIGO and PIFELTRO provide two new options for the treatment of HIV-1 in appropriate treatment-naïve adult patients.
2018-07-24	GlaxoSmithKline	Results ViiV Healthcare presents phase III data at AIDS 2018 from landmark GEMINI studies showing two-drug regimen of dolutegravir and lamivudine has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no emergence of resistance gsk.com ↗ The studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA <50c/mL, a standard measure of HIV control, at Week 48.
2018-06-14	GlaxoSmithKline	Results ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients gsk.com ↗ The studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA <50 copies per millilitre (c/mL), a standard measure of HIV control, at Week 48.
2018-03-05	Gilead Sciences	Results Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine gilead.com ↗ Through Week 48, Biktarvy was found to be statistically non-inferior to ABC /DTG/3TC with a numerically lower incidence of mild or moderate study drug-related adverse events and no treatment-emergent resistance.
2018-01-08	Merck Sharp & Dohme LLC	Regulatory FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection merck.com ↗ The FDA has set a target action date of Oct. 23, 2018, for both applications under the Prescription Drug User Fee Act (PDUFA).
2017-10-04	Gilead Sciences	Results Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens gilead.com ↗ In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks.
2017-07-25	Merck Sharp & Dohme LLC	Results Merck’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection merck.com ↗ In addition, through 48 weeks, statistically significantly fewer patients taking DOR/3TC/TDF reported pre-specified categories of neuropsychiatric events (dizziness, sleep disorders and disturbances, and inability to think clearly or concentrate) than patients receiving the EFV/FTC/TDF regimen.
2017-07-24	Gilead Sciences	Results Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ At Week 48, 92.4 percent (n=290/314) of patients taking BIC/FTC/TAF and 93.0 percent (n=293/315) of patients taking ABC /DTG/3TC achieved the primary endpoint
2016-07-18	GlaxoSmithKline	Results ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV gsk.com ↗ Results show statistically superior viral suppression (HIV-1 RNA <50 c/mL) rates at week 48: 82% versus 71% (adjusted difference 10.5%, 95% CI: 3.1%-17.8%, p=0.005) respectively.1
2014-09-03	GlaxoSmithKline	Regulatory ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV gsk.com ↗ We are delighted with today’s approval that offers people living with HIV in Europe the first single-pill regimen containing dolutegravir.
2014-08-22	GlaxoSmithKline	Regulatory ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection gsk.com ↗ ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.
2014-06-27	GlaxoSmithKline	Regulatory Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV gsk.com ↗ the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine)
2014-06-24	Merck Sharp & Dohme LLC	Regulatory FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine merck.com ↗ Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for a fixed-dose combination (FDC) of raltegravir with lamivudine for the treatment of HIV-1 infection (MK-0518B) has been accepted for standard review by the U.S. Food and Drug Administration (FDA).
2013-10-25	GlaxoSmithKline	Regulatory ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV gsk.com ↗ ViiV Healthcare today announced the submission of a regulatory application in Europe for its investigational single-tablet regimen (STR) combining dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) for the treatment of people living with HIV.
2013-10-22	GlaxoSmithKline	Regulatory ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV gsk.com ↗ ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1.
2012-07-11	GlaxoSmithKline	Results Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV gsk.com ↗ The study demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla®.
2011-05-26	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of Generic Combivir Tablets: Launch Expected in Fourth Quarter 2011 tevapharm.com ↗
2008-10-29	Bristol-Myers Squibb	Results Use of Investigational Agent Entecavir Demonstrated Statistically Significant Improvement in Liver Histology and Viral Suppression Compared to Lamivudine in Chronically Infected Hepatitis B E-Antigen (HBeAg) Positive Patients bms.com ↗ At Week 48, histologic improvement was observed in 72 percent of patients taking entecavir compared to 62 percent of patients receiving lamivudine using the Knodell necroinflammatory score analysis.
2008-04-24	Gilead Sciences	Results Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B gilead.com ↗ The studies' primary efficacy endpoints were reached at 48 weeks, at which time Viread demonstrated superior efficacy over Hepsera.
2007-10-29	Gilead Sciences	Results Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients gilead.com ↗ Patients in both study arms maintained virological suppression at 48 weeks.
2006-08-17	Vertex Pharmaceuticals Incorporated	Results Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ This month, The Lancet published results of a study showing that HIV regimens using LEXIVA (Telzir) Tablets+ritonavir and Kaletra (lopinavir/ritonavir) Capsules both given twice-daily had comparable (non-inferior) efficacy and tolerability in adults who had no previous exposure to HIV medicines.
2006-08-14	Gilead Sciences	Results 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com ↗
2006-01-18	Gilead Sciences	Results Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com ↗ Publication Describes Superior Viral Suppression with Fewer Adverse Events Leading to Discontinuation for Patients Taking Viread and Emtriva at 48 Weeks
2005-02-03	Gilead Sciences	Results Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV gilead.com ↗ Gilead Sciences (Nasdaq:GILD) today announced preliminary 48-week data from the company's Study 934.
2004-10-31	Gilead Sciences	Results Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC gilead.com ↗ Although both triple-drug regimens are relatively convenient, we observed a difference in the two arms, with more patients discontinuing in the Combivir group due to adverse events.
2004-08-26	Gilead Sciences	Results Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV gilead.com ↗ Preliminary results show a statistically significant difference favoring Viread/Emtriva in the percentage of patients who achieved and maintained HIV RNA less than 400 copies/mL at 24 weeks, based on the FDA Time to Loss of Virologic Response algorithm (TLOVR).
2003-02-11	Gilead Sciences	Results 96-Week Data From Phase III Study Show Long-Term Efficacy With Reduced Risk of Lipid and Metabolic Changes for Viread Versus Stavudine in Treatment-Naive HIV Patients gilead.com ↗ The 96-week results presented today show that the Viread and stavudine arms reduced HIV RNA to less than 400 copies/mL in 82 and 78 percent of patients respectively, using the most conservative "missing equals failure" analysis.
2002-11-04	Gilead Sciences	Results New Data Demonstrate Antiviral Activity of Gilead's Hepsera in Patients with Lamivudine-Resistant Chronic Hepatitis B gilead.com ↗ Patients treated with lamivudine alone did not show significant virological, biochemical or serological benefit compared with their baseline values.
2001-06-05	Gilead Sciences	Results Gilead Sciences Presents Data Characterizing Resistance Profile of Tenofovir DF, Investigational Agent for the Treatment of HIV gilead.com ↗ The results demonstrate that chain-terminator removal occurs more readily with nucleosides than nucleotides and may contribute to the higher-level of resistance associated with nucleosides.
1998-09-23	Gilead Sciences	Results Gilead Sciences Provides Update on PREVEON® Clinical Program for the Treatment of HIV gilead.com ↗ These data demonstrate that PREVEON has durable anti-HIV activity in treatment-experienced patients, including those infected with strains of HIV resistant to most currently approved therapies.

All press releases naming this drug 103 releases

Date	Issuer	Release
Show all 103 releases opens the full record — a long page

Evidence & citations 35 cited values

Every value below carries the sentence it was read from. 634 sources stand behind the page.

Field	Value	Cited text
Known as	lamivudine	“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ 560 “Participants on any stable second-generation integrase strand transfer inhibitor-based 3DR regimen with HIV-1 RNA < 50 copies/mL plasma for at least 3 months were randomized to...” PMID 39226296 ↗ Feb 2025 “This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed...” NCT00085943 ↗ “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine,...” NCT00214435 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir...” NCT05729568 ↗ “Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine...” NCT06602622 ↗ “NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940 ↗ Show 550 more sources
Known as	3-thiacytidine	“Lamivudine (also known as 3-thiacytidine: 3TC) is an antiviral medication given as a pill once a day for twelve months.” NCT00001457 ↗
Known as	3TC	“First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV...” NCT03076359 ↗ 227 “The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations,...” NCT00116298 ↗ “Multi-center Study to Evaluate Virological Efficacy, Safety Tolerability, Drug Exposure and Patients' Reported Outcomes Over 48 Weeks Following Randomization to 2-drug Therapy...” NCT05735535 ↗ “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ “Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release...” NCT00116116 ↗ “BACKGROUND: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For...” PMID 37539061 ↗ Jul 2023 “An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS...” NCT00002368 ↗ “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “The investigators propose to evaluate the safety of combination therapy comprising the three nucleoside analog reverse-transcriptase inhibitors (NRTIs) zidovudine (AZT),...” NCT02363452 ↗ Show 217 more sources
Known as	3TC: lamivudine: Epivir	“3TC: lamivudine: Epivir” NCT02028676 ↗
Known as	BCH 189, (-)-	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Epivir	“A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to...” NCT00038220 ↗ 10 “100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) +...” NCT00002369 ↗ “combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day.” NCT02527096 ↗ “Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott)” NCT01599364 ↗ “150 mg lamivudine (Epivir tablets, GlaxoSmithKline)” NCT00966160 ↗ “Epivir (Lamivudine; 3TC)” NCT00002234 ↗ “Lamivudine (Epivir® )” NCT03491553 ↗ “Lamiduvine (Epivir)” NCT00885482 ↗ “Epivir (Lamivudine)” NCT00002168 ↗ NCT00979706 ↗ NCT00135382 ↗
Known as	Epivir-hbv	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	GR109714X	“3TC (Lamivudine; GR109714X) Open-Label Program” NCT00002108 ↗ 1 “Lamivudine (3TC; GR109714X) Monotherapy” NCT00002320 ↗
Known as	LAM	“BACKGROUND: The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable...” PMID 29329305 ↗ Jan 2018 5 “The objective of this prospective randomized clinical trial was to compare the strategy of HBV monotherapy with lamivudine (LAM) or tenofovir disoproxil fumarate (TDF) versus...” PMID 18697216 ↗ Oct 2008 “Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections.” PMID 32460460 ↗ May 2020 “Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162 ↗ “Lamivudine (LAM)” NCT01095835 ↗ “Lamivudine (LAM)” NCT00316719 ↗
Known as	Lamivudina	“Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil” NCT07618507 ↗
Known as	Lamivudine (3TC)	“Lamivudine (3TC)” NCT01338025 ↗
Known as	lamivudine (zeffix)	“lamivudine (zeffix)” NCT01804387 ↗ 2 “Lamivudine (Zeffix)” NCT01546116 ↗ “Lamivudine (Zeffix)” NCT01023217 ↗
Known as	lamivudine 100 mg tablets (GlaxoSmithKline);	“lamivudine 100 mg tablets (GlaxoSmithKline);” NCT01894269 ↗
Known as	Lamivudine component of /zidovudine teva	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of cimduo	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of combivir	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of delstrigo	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of dovato	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of dutrebis	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of epzicom	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of kivexa	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of symfi	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of temixys	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of triumeq	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine component of trizivir	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine teva	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudine teva pharma b.v.	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Lamivudinum	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	LVD	“we conducted a randomized controlled trial in which CHB patients with spontaneous SAE were randomized to receive lamivudine (LVD) or entecavir (ETV)” PMID 28671553 ↗ 2018
Known as	NSC-760061	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Virolam	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Known as	Zeffix	ChEMBL registry synonym — accepted as the source's own label CHEMBL141 ↗
Action	Inhibit	“nucleoside reverse transcriptase inhibitors” NCT00000882 ↗
Modality	Other / unclassified	“HIV nucleoside reverse transcriptase inhibitors (NRTI)” PMID 16103764 ↗ Sep 2005
Route	Oral	“Oral 3TC.” NCT00000878 ↗